SCC641
HCI-EC-23 Human Endometrial Cancer Cell Line
Synonym(e):
HCI-EC-23 Human Endometrial Cancer Cell Line
About This Item
Empfohlene Produkte
Biologische Quelle
human
Qualitätsniveau
Verpackung
vial of ≥1 x 10^6 vial (viable cells per vial)
Hersteller/Markenname
Millipore
Methode(n)
cell culture | mammalian: suitable
Versandbedingung
liquid nitrogen
Lagertemp.
−196°C
Anwendung
- Each vial contains > 1X106 viable cells.
- Cells are tested negative for infectious diseases by Essential CLEAR Panel by Charles River Animal Diagnostic Services.
- Cells are verified to be of human origin and negative for interspecies contamination from human, rat, Chinese hamster, Golden Syrian hamster, and nonhuman primate (NHP) as assessed by a Contamination Clear panel by Charles River Animal Diagnostic Services
- Cells are negative for mycoplasma contamination.
Leistungsmerkmale und Vorteile
Zielbeschreibung
A variety of cell lines have been created from Type I tumors such as Ishikawa cells. However, many of these cell lines have lost ERα expression and estrogen response. The limited availability of ERα expressing endometrial cell lines limits the variety of genetic backgrounds for understanding endometrial cancer. Patient derived xenografts (PDX) have increased the capability to produce hormone-responsive models but lack some of the benefits of a cell line model.
The HCI-EC-23 human endometrial cancer cell line was derived by generating a PDX cell line in a mouse model. Cells from an endometrial carcinoma sample were injected into immunodeficient mice and grown in the mouse model before being harvested. PDX samples were dissociated, grown on collagen coated plates and selected for predominantly human (99%) cells which became the HCI-EC-23 cell line. These cells retain ER expression and estrogen-responsiveness in vitro and in vivo. The cell line contains important mutations relevant to endometrial carcinomas including mutations at PTEN, PIK3CA, ARID1A, CTCF, and ATM, but remains wild-type for PIK3R1, CTNNB1, KRAS and TP53. Progesterone receptor genes and estrogen receptor genes also remain wild-type.
Estrogen responsiveness was tested in the HCI-EC-23 cell line by transfecting cells with a luciferase reporter under control of tandem estrogen response elements and treating cells with E2. HCI-EC-23 cells also showed estrogen responsiveness to 4-hydroxy-tamoxifen (4OHT) treatment which is consistent with observations of endometrial response.
Source: Primary tumor was obtained from a 66-year old woman diagnosed with Grade 2 Stage 1A endometrioid endometrial carcinoma which was later cloned into a mouse PDX model. A predominantly human (99%) cell outgrowth was used to derive the HCI-EC-23 human endometrial cancer cell line.
References
1. Rush, C.M., Blanchard, Z., Polaski, J.T. et al. Characterization of HCI-EC-23 a novel estrogen- and progesterone-responsive endometrial cancer cell line. Sci Rep 12, 19731 (2022).
Lagerung und Haltbarkeit
Sonstige Hinweise
Haftungsausschluss
Lagerklassenschlüssel
10 - Combustible liquids
WGK
WGK 2
Flammpunkt (°F)
Not applicable
Flammpunkt (°C)
Not applicable
Analysenzertifikate (COA)
Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.
Besitzen Sie dieses Produkt bereits?
In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.
Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..
Setzen Sie sich mit dem technischen Dienst in Verbindung.